SFL has proactively supported the initiation of two associations (Medtech & Pharma Platform [MPP] and Rare Disease Action Forum [RDAF]) and acts as secretariat of both, organizing regular events and stakeholder meetings.
Medtech & Pharma Platform (MPP)
The Medtech & Pharma Platform is a European industry Association for the medtech, pharmaceutical and tech sectors. By establishing a forum for the exchange of knowledge and collaboration in technology and regulatory areas, the Association’s aim is to enhance interaction between theese industries in order to reduce time to market for combined products, improve access to innovative products, better match patients’ needs and expand business opportunities.
To achieve these goals the MPP Association organizes an international conference to foster cross-sectoral exchanges, regularly offers expert trainings on regulatory developments and product development, and engages in advocacy work.
Rare Disease Action Forum (RDAF)
The Rare Disease Action Forum is an association that serves as a platform to exchange ideas and define actions on how to raise awareness of rare diseases and improve access to innovative therapies for patients with rare diseases in Switzerland. The RDAF organizes multi-stakeholder meetings, bringing together experts from companies developing treatments, diagnostics, or providing any related service and additional experts in the field of rare diseases.
Swiss Medtech represents the interests of the Swiss medtech industry, aiming to maintain international competitiveness, innovative capacity, and strengthen the domestic market.
The Round Table on Antibiotics is a multidisciplinary Swiss non-profit association gathering members from academia, industry and decision makers, which aims to provide solutions in the fight against antimicrobial resistance.
The organization promotes public awareness of antibiotic resistance, supports policymaking, and seeks to facilitate projects that require a multidisciplinary approach. It focuses on fostering financial models for the development of new antibiotics, strengthening the resilience of antibiotic supply chains, and securing the supply of antibiotics.